Search
Allylestrenol
go.drugbank.com/drugs/DB01431InvestigationalIt is widely marketed throughout Europe, including Russia and many other European countries, and is also available in Japan, Hong Kong, India, Bangladesh, Indonesia, and much of Southeast Asia, though
Belnacasan
go.drugbank.com/drugs/DB05507InvestigationalVX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198).
Palmidrol
go.drugbank.com/drugs/DB14043InvestigationalNutraceuticalPalmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets).
Nedaplatin
go.drugbank.com/drugs/DB13145ApprovedInvestigationalIt is less nephrotoxic than [DB00515] but has proven equally effective. It was approved for use in Japan in 1995.
Topotecan
go.drugbank.com/drugs/DB01030ApprovedInvestigationalIt works by inhibiting DNA topoisomerases, type I.
Phentolamine
go.drugbank.com/drugs/DB00692ApprovedInvestigationalPhentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointe...
Sepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigational[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … It is a natural precursor of the enzymatic co-factor tetrahydrobiopterin (BH4), which activates PAH and helps reduce blood phenylalanine levels by enhancing the conformational stability of misfolded PAH
Baclofen
go.drugbank.com/drugs/DB00181ApprovedInvestigationalAlthough originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.
Peginterferon alfa-2a
go.drugbank.com/drugs/DB00008ApprovedInvestigationalPeginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C. … Approved in 2002 by the FDA, Pegasys is indicated for the treatment of HCV with [DB00811] or other antiviral drugs [FDA Label].